Drugs / JZP150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05178316 | Dec 2021 → Dec 2023 | post-traumatic stress disorder | Jazz Pharmaceuticals | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | Jazz Pharmaceuticals | Results Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder jazzpharma.com ↗
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-21 | Jazz Pharmaceuticals | Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder jazzpharma.com ↗ |
| 2021-12-30 | Jazz Pharmaceuticals | Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder jazzpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JZP150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05178316 ↗ |
| Action | Inhibit | “highly selective inhibitor of fatty acid amide hydrolase (FAAH)” NCT05178316 ↗ |
| Route | Oral | “Oral administration of JZP150 once daily in the morning” NCT05178316 ↗ |
| Target | FAAH | “inhibitor of fatty acid amide hydrolase (FAAH)” NCT05178316 ↗ |